Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

BACKGROUND: Adjuvant bisphosphonates are associated with improved breast cancer survival in postmenopausal patients. Addition of zoledronic acid (ZA) to neoadjuvant chemotherapy did not improve pathological complete response in the phase III NEOZOTAC trial. Here we report the results of the secondar...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Breast Cancer Res
Main Authors: de Groot, Stefanie, Pijl, Hanno, Charehbili, Ayoub, van de Ven, Saskia, Smit, Vincent T. H. B. M., Meershoek-Klein Kranenbarg, Elma, Heijns, Joan B., van Warmerdam, Laurence J. C., Kessels, Lonneke W., Dercksen, M. Wouter, Pepels, Manon J. A. E., van Laarhoven, Hanneke W. M., Vriens, Birgit E. P. J., Putter, Hein, Fiocco, Marta, Liefers, Gerrit-Jan, van der Hoeven, Jacobus J. M., Nortier, Johan W. R., Kroep, Judith R.
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2019
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6712613/
https://ncbi.nlm.nih.gov/pubmed/31455425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1180-6
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker